<DOC>
	<DOCNO>NCT00642720</DOCNO>
	<brief_summary>Study Synopsis Study Title : Double blind , single centre , cross-over study effect weekly subcutaneous administration 40 mg pegvisomant placebo quality life insulin sensitivity acromegalic patient normal serum IGF-I concentration long-term treatment long-acting somatostatin analog Study Objectives : 1 . To determine whether addition weekly pegvisomant administration improve quality life 2 . To determine whether addition weekly pegvisomant administration improve insulin sensitivity Study Population : Acromegalic patient , normalized serum IGF-I level upper 25 centile normality long-term treatment monthly injection long-acting somatostatin analogue Number Subjects : 20 Procedures : - Patients treatment Sandostatin LAR ( SL ) 20 - 30 mg per month i.m . patient treatment Lanreotide autosolution ( LA ) 90 - 120 mg deep s.c. enrol . - For 4 month , subject also receive weekly s.c. injection either placebo fix dose 40 mg pegvisomant - After 4 week wash-out period , patient switch either placebo pegvisomant pegvisomant placebo - Before , 2 4 month treatment period , serum efficacy parameter quality life ( AcroQol ™/ PASQ™ ) assess . - Before 4 month treatment period , pituitary tumor size insulin sensitivity ( HOMA/SIGMA model ) assess . Duration study : 9 month Hypothesis : •We postulate co-administration growth hormone receptor antagonist pegvisomant improve QoL insulin sensitivity</brief_summary>
	<brief_title>Change Quality Life After Addition Weekly 40 mg Pegvisomant/Placebo Controlled Acromegalic Patients</brief_title>
	<detailed_description>Introduction Both lanreotide ( Somatulin Autosolution ™ ( SL ) ) octreotide ( Sandostatin LAR ™ ( LAR ) ) equally effective control disease activity acromegalic subject normalization serum insulin-like growth factor-I ( IGF-I ) level roughly 65 % . However , SL inject deep intramuscular injection , LA inject deep subcutaneous injection . Physicians , involve treatment acromegalic patient know biochemical control disease patient necessarily mean patient stop complain . To address issue , Sonino co-worker study several symptom questionnaire effect quality life ( QoL ) SL . Together significant decrease growth hormone ( GH ) IGF-I , treatment SL significantly improve psychological distress , well-being social fear ( 1 ) . In another study efficacy novel GH receptor antagonist pegvisomant low serum IGF-I concentration questionnaire evaluate five clinical sign symptom acromegaly show dose dependent significant difference placebo ( 2 ) . Recently , Webb co-worker report successful development disease-specific questionnaire suitable measure health-related quality life acromegaly ( ACROQOL ) ( 3 ) . No clear biochemical parameter appear available correlate well disease activity relate quality life ( 4 ) . At time , serum GH concentration serum total IGF-I level , QoL , use parameter determine dose Sandostatin LAR , available medical therapy acromegaly ( 5-8 ) . The growth hormone receptor antagonist pegvisomant monotherapy daily normalize IGF-I virtually acromegalics ( 9 ; 10 ) , pegvisomant monotherapy also costly . Recently , report result 42-week dose-finding study efficacy combination long-acting somatostatin analogue monthly pegvisomant weekly 26 patient active acromegaly . Pegvisomant dose increase IGF-I level normalize weekly dose 80 mg reach . IGF-I level normalize 25 ( 95 % ) median weekly dose 60 mg pegvisomant . There sign pituitary tumor growth mild elevation liver enzymes observe 10 patient ( 38 % ) ( 11 ) . One potential advantage combine pegvisomant somatostatin analogue pegvisomant monotherapy improve insulin sensitivity compare somatostatin analogue ( 12 ; 13 ) , although unclear yet whether long-term pegvisomant administration would improve insulin sensitivity normal subject ( 13 ; 14 ) . Therefore , one might expect pegvisomant monotherapy beneficial effect insulin sensitivity , compare combination pegvisomant somatostatin analogue , latter one decrease insulin sensitivity several mechanism ( 13 ; 15 ) . Conclusion : - So-called biochemically well control acromegalic subject normal serum IGF-I concentration frequently still impaired QoL . - These subject , control long-acting somatostatin analog impaired insulin sensitivity pharmacological property somatostatin analog . - We postulate co-administration growth hormone receptor antagonist pegvisomant improve QoL insulin sensitivity Objectives : 1 . To determine whether addition weekly pegvisomant administration improve quality life 2 . To determine whether addition weekly pegvisomant administration improve insulin sensitivity Description procedure : - Patients treatment Sandostatin LAR ( SL ) 20 - 30 mg per month i.m . patient treat Lanreotide autosolution ( LA ) 90 - 120 mg deep s.c. enrol . - For 4 month , randomization , subject also receive weekly s.c. injection either placebo fix dose 40 mg pegvisomant - After 4 week wash-out period , patient switch either placebo pegvisomant pegvisomant placebo - Before , 2 4 month treatment period , serum efficacy parameter quality life ( AcroQol ™ , general QoL questionaire PASQ Signs Symptoms ) assess . - Before 4 month treatment period , pituitary tumor size insulin sensitivity ( HOMA/SIGMA model ( 16 ) ) assess . Subjects Twenty acromegalic subject see regular interval out-patient facility ask participate . All subject see Clinical Research Unit . Inclusion criterion : - Active acromegaly . - Serum total IGF-I level must normalize long-term treatment long-acting somatostatin analog - Age 18 80 Exclusion criterion : - Any contra-indication use long-acting somatostatin analog , e.g . use anti-coagulants . - Subjects pituitary tumor compress optic chiasm - Patients insulin dependent diabetes - Patients cancer - Patients kidney- liver function disturbance - Fertile female patient refuse take contraceptive study Study procedure Visit 1 ; baseline ( week 0 ; 1 day prior next monthly injection long-acting SRIF analog ) ) - Review inclusion exclusion criterion - Obtain write informed consent - Conduct medical history physical examination ; record vital sign . - Blood sampling : fasting IGF-I , insulin , GH , glucose , HbA1c , liver function , lipid profile , free fatty acid , pegvisomant level , pregnancy test female . - QoL assessment ( AcroQol™/PASQ ™ ) - MRI ( recent MRI &lt; 3 month also acceptable ) - Injection usual SL LA dose - randomization - Start weekly injection 40 mg pegvisomant placebo ( 16 injection total ) Visit 2 , 3 ( week 8 16 ; one day prior weekly study drug/placebo injection ) - Blood sampling : fasting IGF-I , insulin , GH , glucose , HbA1c , liver function , lipid profile , free fatty acid , pegvisomant level - QoL assessment ( AcroQol™/PASQ ™ ) - After week 16 , patient 4 week wash-out period - MRI Visit 4 ( week 20 ; end wash-out ) - Blood sampling : fasting IGF-I , insulin , GH , glucose , HbA1c , liver function , lipid profile , free fatty acid , pegvisomant level - Return study medication drug accountability - QoL assessment ( AcroQol™/PASQ ™ ) - Start second co-treatment period weekly s.c injection either placebo 40 mg fixed-dose pegvisomant ( 16 weekly injection ) Visit 5 , 6 ( week 28 36 ; one day prior weekly study drug/placebo injection ) - Blood sampling : fasting IGF-I , insulin , GH , glucose , HbA1c , liver function , lipid profile , free fatty acid , pegvisomant level - Return study medication drug accountability - QoL assessment ( AcroQol™/PASQ ™ ) - MRI</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Active acromegaly . Serum total IGFI level must normalize longterm treatment longacting somatostatin analog Age 18 80 Any contraindication use longacting somatostatin analog , e.g . use anticoagulant . Subjects pituitary tumor compress optic chiasm Patients insulin dependent diabetes Patients cancer Patients kidney liver function disturbance Fertile female patient refuse take contraceptive study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>